Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
CC transcript
AGENUS INC (AGEN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "Agenus Reports Second Quarter 2023 Results"
05/09/2023 8-K Quarterly results
Docs: "Agenus Provides Corporate Update and First Quarter 2023 Financial Results"
03/14/2023 8-K Quarterly results
Docs: "Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives Botensilimab plus balstilimab showed overall response rates of 23% in microsatellite stable colorectal cancer , 50% in PD-1 refractory non-small cell lung cancer and in seven additional metastatic, late-line cancers in a total of more than 300 patients Randomized Phase 2 trials in MSS CRC, melanoma, and pancreatic cancers are underway; a confirmatory phase 3 trial in MSS CRC is expected to be launched in 2023 Data demonstrating clinical benefit in MSS CRC, NSCLC, ovarian cancer, and sarcomas were presented in plenary sessions at ESMO GI, SITC, and CTOS in 2022, and in a late-breaking oral session at ASCO GI in January 2023 Existing corporate collaborations have potential to generate up to $2.7B ..."
11/08/2022 8-K Quarterly results
Docs: "Agenus Provides Corporate Update and Third Quarter 2022 Financial Report"
08/09/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
03/01/2022 8-K Quarterly results
11/09/2021 8-K Quarterly results
Docs: "Agenus Corporate Update and Third Quarter 2021 Financial Report Clinical results presented at SITC show that AGEN1181, as a monotherapy and in combination with balstilimab, shows durable responses in 9 cancer types, including patients whose cancers have recurred following PD-1 therapy Agenus will commence Phase 2/3 trials of AGEN1181 and balstilimab in colorectal and several gynecological cancers Agenus’ cell therapy affiliate, MiNK Therapeutics , launched as a publicly traded company with >$40 million raised to accelerate clinical development AGEN1777, an Fc-enhanced TIGIT bispecific antibody, entered Phase 1 development, triggering a $20M milestone payment from Bristol Myers Squibb After successfully achieving clinical milestones and passing FDA inspections, Agenus withdrew its BLA for b..."
05/06/2021 8-K Quarterly results
10/29/2020 8-K Quarterly results
Docs: "Agenus R&D Update & Third Quarter Financial Report Balstilimab rolling BLA filing and FDA review underway COVID-19 trial open with patients in screening for iNKT Cell Therapy New data and clinical responses with AGEN1181 to be presented at SITC on NOV11 LEXINGTON, Mass., Oct. 29, 2020 -- Agenus Inc. , an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate and optimize immune response to cancers and infections, today provided a corporate update and reported financial results for the third quarter of 2020. Balstilimab BLA filing initiated and FDA review is underway; data presented at ESMO Balstilimab monotherapy trial achieves response rates of 19% in PD-L1 positive tumors and 14% in PD-L1 positive and nega..."
08/10/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
03/12/2020 8-K Quarterly results
11/04/2019 8-K Quarterly results
Docs: "Through AgenTus Therapeutics,"
08/08/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 August 8, 2019 Date of Report AGENUS INC. DELAWARE 000-29089 06-1562417 File Number) Identification No.) 3 Forbes Road Lexington, MA 02421 781-674-4400 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under t...",
"Agenus Reports Second Quarter 2019 Financial Results and Provides Corporate Update"
05/09/2019 8-K Quarterly results
Docs: "Select Financial Information"
03/14/2019 8-K Quarterly results
Docs: "Select Financial Information"
11/06/2018 8-K Quarterly results
Docs: "Select Financial Information"
08/09/2018 8-K Quarterly results
Docs: "Select Financial Information"
05/07/2018 8-K Quarterly results
Docs: "Select Financial Information"
03/15/2018 8-K Quarterly results
Docs: "Summary Consolidated Financial Information Condensed Consolidated Statements of Operations Data Three months ended December 31, Year ended December 31, 2017 2016 2017 2016 Revenue $ 8,354 $ 5,576 $ 42,877 $ 22,573 Operating expenses: Research and development 31,872 25,983 116,125 94,971 General and administrative 9,784 8,670 33,741 33,126 Non-cash contingent consideration fair value adjustment 1,953 Operating loss Other expense, net Net loss Dividends on Series A convertible preferred stock Net loss attributable to common stockholders $ $ $ $ Per common share data, basic and diluted: Net loss attributable to common stockholders $ $ $ $ Weighted average number of common shares outstanding, basic and diluted 100,961 87,416 98,415 87,070 Condensed Consolidated Balance Sheet Data De..."
08/03/2017 8-K Quarterly results
05/04/2017 8-K Form 8-K - Current report
03/09/2017 8-K Form 8-K - Current report
10/27/2016 8-K Form 8-K - Current report
07/28/2016 8-K Form 8-K - Current report
04/28/2016 8-K Form 8-K - Current report
03/03/2016 8-K Form 8-K - Current report
10/27/2015 8-K Quarterly results
Docs: "Agenus Reports Third Quarter 2015 Financial Results"
07/23/2015 8-K Quarterly results
Docs: "Agenus Reports Second Quarter 2015 Financial Results"
04/23/2015 8-K Quarterly results
Docs: "Agenus Reports First Quarter 2015 Financial Results"
10/31/2014 8-K Quarterly results
Docs: "Agenus Reports Third Quarter 2014 Financial Results"
07/24/2014 8-K Quarterly results
Docs: "Agenus Reports Second Quarter 2014 Financial Results"
05/08/2014 8-K Quarterly results
Docs: "Agenus Reports First Quarter 2014 Financial Results"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy